Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Total Non-Current Liabilities: 2016-2023

Historic Total Non-Current Liabilities for Cytokinetics (CYTK) over the last 7 years, with Dec 2023 value amounting to $1.2 billion.

  • Cytokinetics' Total Non-Current Liabilities was N/A to $2.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 billion, marking a year-over-year change of. This contributed to the annual value of $1.2 billion for FY2023, which is 7.92% up from last year.
  • According to the latest figures from FY2023, Cytokinetics' Total Non-Current Liabilities is $1.2 billion, which was up 7.92% from $1.1 billion recorded in FY2022.
  • Cytokinetics' 5-year Total Non-Current Liabilities high stood at $1.2 billion for FY2023, and its period low was $157.5 million during FY2019.
  • For the 3-year period, Cytokinetics' Total Non-Current Liabilities averaged around $975.0 million, with its median value being $1.1 billion (2022).
  • Data for Cytokinetics' Total Non-Current Liabilities shows a peak YoY skyrocketed of 150.87% (in 2019) over the last 5 years.
  • Cytokinetics' Total Non-Current Liabilities (Yearly) stood at $157.5 million in 2019, then reached $593.0 million in 2021, then spiked by 89.15% to $1.1 billion in 2022, then rose by 7.92% to $1.2 billion in 2023.